The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should we treat asymptomatic (‘early’) myelofibrosis with JAKi?

Sep 8, 2020

During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee member, Ruben A. Mesa, UT Health San Antonio, San Antonio, US, about whether it is a good idea to use JAK inhibitors (JAKi) in early, or asymptomatic, myelofibrosis (MF).

Should we treat asymptomatic (‘early’) myelofibrosis with JAKi?

JAKi were originally used in more advanced cases of MF and showed positive results in these patients. Now the use of JAKi, specifically ruxolitinib, is being applied to low risk patients.